DBV Technologies EBIT par action

Que fait DBV Technologies ? DBV Technologies S.A. generates revenue through its clinical-stage biopharmaceutical products, primarily Viaskin Peanut and Viaskin Milk, which are in Phase 3 and Phase 1/2 trials respectively for treating peanut and cow's milk allergies. The company also develops the Viaskin technology platform for food allergy treatment and collaborates with Nestlé Health Science on MAG1C, a diagnostic patch for non-IgE mediated CMPA in infants. Revenue streams include product development partnerships, such as the collaboration with Nestlé Health Science, and potential future sales of approved therapies targeting allergic conditions. The primary buyers of DBV's products and technology are healthcare providers, hospitals, and allergy specialists who treat patients with IgE-mediated allergies and eosinophilic esophagitis. The company's focus on pediatric and adult allergy markets, particularly for peanut and milk allergies, positions it to serve patients requiring immunotherapy solutions. Additionally, diagnostic tools like MAG1C target healthcare professionals involved in early allergy diagnosis for infants and toddlers. DBV Technologies operates within the biopharmaceutical sector, specializing in epicutaneous immunotherapy for food allergies. Its product pipeline includes Viaskin Peanut for peanut allergy treatment, Viaskin Milk for cow's milk allergy, and Viaskin technology for broader food allergy applications. The company's collaboration with Nestlé Health Science on MAG1C represents a strategic partnership to expand diagnostic capabilities in pediatric allergy care, aligning with its research focus on IgE-mediated conditions and eosinophilic esophagitis. DBV Technologies est l'une des entreprises les plus populaires sur Eulerpool.